SCHEMBL4918853

SCHEMBL4918853

COc1ccc(Nc2nccc(-c3ccc(C(=O)NC4CCc5ccccc54)s3)n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.49
TAS1R3 Q7RTX0 2/20 0.45
TAS1R1 Q7RTX1 2/20 0.45
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 1/20 0.42
PIK3C3 Q8NEB9 1/20 0.42
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
CHRM4 P08173 1/20 0.41
BTK Q06187 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
AKT1 P31749 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5000368 0.85 AKT3 (0.54) TAS1R3TAS1R1CNR1CNR2CHRM4
SCHEMBL5000133 0.80 TAS1R3 (0.60) TAS1R3TAS1R1MEN1KMT2AALDH1A1
SCHEMBL4929201 0.79 TAS1R3 (0.51) HPGDSTAS1R3TAS1R1ALDH1A1CNR1
SCHEMBL3972858 0.76 AKT3 (0.57) MEN1KMT2ACNR2AURKBIKBKB
SCHEMBL4929463 0.76 AURKB (0.52) MEN1KMT2APIK3CAPIK3CBPIK3CG
SCHEMBL4929513 0.76 AURKB (0.52) MEN1KMT2APIK3CAPIK3CBPIK3CG
SCHEMBL4925751 0.75 AKT3 (0.63) MEN1KMT2AALDH1A1CNR2CHRM4
SCHEMBL3980987 0.75 AKT3 (0.71) NPC1RAB9AIKBKB
SCHEMBL14007238 0.74 TAS1R3 (0.54) TAS1R3TAS1R1PDE4APDE4BPDE4C
SCHEMBL4928236 0.74 MAPT (0.51) ALDH1A1BTKPTK2IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293716-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 US disclosed
US-20080293716-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 US disclosed
US-20080293716-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 US disclosed
US-20080194561-A1 carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. SMITHKLINE BEECHAM CORPORATION 2008-08-14 US disclosed
US-20080194561-A1 carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. SMITHKLINE BEECHAM CORPORATION 2008-08-14 US disclosed
EP-1708697-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-11-28 EP disclosed
EP-1708697-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-11 EP disclosed
WO-2005074642-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293716-A1 Chemical Compounds CYP11B2, CYP11B1, REN HPGDS 1200/4885TAS1R3 3465/4885TAS1R1 3059/4885
US-20080194561-A1 carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. AURKA, AURKC, AURKB HPGDS 3724/4885TAS1R3 4820/4885TAS1R1 4695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.